Literature DB >> 10940371

Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung.

M R Corboz1, M A Rivelli, R W Egan, D Tulshian, J Matasi, A B Fawzi, L Benbow, A Smith-Torhan, H Zhang, J A Hey.   

Abstract

The isolated perfused guinea pig lung was used to investigate the effect of nociceptin against bronchoconstriction elicited by endogenous and exogenous tachykinins. The opioid receptor-like 1 (ORL1) receptor agonist, nociceptin/orphanin FQ (0.001-1 microM) produced a dose-related inhibition of the capsaicin-induced bronchoconstriction (10(-5)-10(3) microg) in isolated guinea pig lung (P<0.05), a response mediated by the release of endogenous tachykinins from lung sensory nerves. The new ORL1 receptor antagonist 1-[(3R, 4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397) (0.3 microM) significantly blocked the inhibitory effect of nociceptin/orphanin FQ (0.01 microM) on capsaicin-induced bronchoconstriction, whereas the non-selective opioid receptor antagonist naloxone (1 microM) had no effect. Nociceptin/orphanin FQ (1 microM) did not affect the bronchoconstriction induced exogenously by the tachykinin NK2 receptor agonist neurokinin A. In conclusion, the present data provide evidence that nociceptin inhibits capsaicin-evoked tachykinin release from sensory nerve terminals in guinea pig lung by a prejunctional mechanism. This inhibitory action occurs independently from activation of opioid receptors. The present study also indicates that J-113397 is a potent ORL1 receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940371     DOI: 10.1016/s0014-2999(00)00505-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.

Authors:  Shailendra R Singh; Nikol Sullo; Maria Matteis; Giuseppe Spaziano; John McDonald; Ruth Saunders; Lucy Woodman; Konrad Urbanek; Antonella De Angelis; Raffaele De Palma; Rachid Berair; Mitesh Pancholi; Vijay Mistry; Francesco Rossi; Remo Guerrini; Girolamo Calò; Bruno D'Agostino; Christopher E Brightling; David G Lambert
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

3.  Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors.

Authors:  R L McLeod; L E Parra; J C Mutter; C H Erickson; G J Carey; D B Tulshian; A B Fawzi; A Smith-Torhan; R W Egan; F M Cuss; J A Hey
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

4.  Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.

Authors:  Bruno D'Agostino; Giuseppina Marrocco; Marilisa De Nardo; Girolamo Calò; Remo Guerrini; Luca Gallelli; Charles Advenier; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

5.  Actions of nociceptin/orphanin FQ and other prepronociceptin products on rat rostral ventromedial medulla neurons in vitro.

Authors:  C W Vaughan; M Connor; E A Jennings; S Marinelli; R G Allen; M J Christie
Journal:  J Physiol       Date:  2001-08-01       Impact factor: 5.182

6.  Nociceptin/orphanin FQ inhibits capsaicin-induced guinea-pig airway contraction through an inward-rectifier potassium channel.

Authors:  Yanlin Jia; Xin Wang; Sonia I Aponte; Maria A Rivelli; Richard Yang; Charles A Rizzo; Michel R Corboz; Tony Priestley; John A Hey
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

7.  Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.

Authors:  Robbie L McLeod; Deen B Tulshian; Donald C Bolser; Geoffrey B Varty; Marco Baptista; Xiomara Fernandez; Leonard E Parra; Jennifer C Zimmer; Christine H Erickson; Ginny D Ho; Yanlin Jia; Fay W Ng; Walter Korfmacher; Xiaoying Xu; John Veals; April Smith-Torhan; Samuel Wainhaus; Ahmad B Fawzi; Theodore M Austin; Margaret van Heek; John A Hey
Journal:  Eur J Pharmacol       Date:  2009-12-16       Impact factor: 4.432

8.  Nociceptin inhibits vanilloid TRPV-1-mediated neurosensitization induced by fenoterol in human isolated bronchi.

Authors:  Christophe Faisy; Emmanuel Naline; Céline Rouget; Paul-André Risse; Emmanuel Guerot; Jean-Yves Fagon; Thierry Chinet; Nicolas Roche; Charles Advenier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-04       Impact factor: 3.000

9.  Nociceptin inhibits airway microvascular leakage induced by HCl intra-oesophageal instillation.

Authors:  Céline Rouget; Yong Yao Cui; Bruno D'Agostino; Christophe Faisy; Emmanuel Naline; Marc Bardou; Charles Advenier
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

Review 10.  Neuroimmune Pathophysiology in Asthma.

Authors:  Gandhi F Pavón-Romero; Nancy Haydée Serrano-Pérez; Lizbeth García-Sánchez; Fernando Ramírez-Jiménez; Luis M Terán
Journal:  Front Cell Dev Biol       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.